Viewing nowCombinationJelostar Tablet 20/5 mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Korea Hutecs Pharmaceutical Co., Ltd.

MFDS item code 202003965 · Approved 2020.05.28 · Insurance code 649104860
Treatment of dyslipidemia and hypertension, inhibition of atherosclerotic progression and cardiovascular disease risk
This medication is used for patients who need to take both olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil helps in treating essential hypertension. Rosuvastatin is used as an adjunct treatment for patients with hypercholesterolemia and hyperlipidemia that are not controlled by diet and exercise. Additionally, it helps slow the progression of atherosclerosis and assists in the treatment of primary dysbetalipoproteinemia. Furthermore, it is effective in reducing the risk of cardiovascular diseases, particularly contributing to a reduction in the risk of stroke, myocardial infarction, and arterial vascular remodeling procedures. Therefore, this medication is used to manage both hypertension and hyperlipidemia together.
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.
Safety and efficacy have not been established in children under 18 years of age.
This medication can cause serious harm or death to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately if pregnancy is confirmed. This medication should not be administered to certain patients, such as individuals allergic to this drug or its components, women who are pregnant or may become pregnant, breastfeeding women, patients with severely impaired kidney function, patients with severe liver disease, or individuals with certain muscle disorders. Due to antihypertensive effects, dizziness or hypotension may occur; thus, caution is needed, especially in patients with decreased blood volume or salt. The initial phase of administration requires careful monitoring. Patients with weak kidney function or kidney transplant recipients should have their kidney function and serum electrolyte levels regularly tested when administered this medication, and caution should be exercised in patients with renal vascular issues. The medication can cause hyperkalemia, so heart failure or patients with kidney dysfunction should closely monitor serum potassium levels. Muscle-related adverse reactions such as muscle pain, myopathy, and, rarely, rhabdomyolysis may occur, so any severe muscle pain or weakness should be reported to healthcare providers immediately. This medication may affect liver function, so patients with liver disease history or abnormal liver enzyme levels should undergo liver function tests both before and during treatment. There may be drug interactions with other medications taken together, so it is essential to inform healthcare providers of any currently prescribed medications, especially when used in conjunction with potassium-sparing diuretics, lithium, or nonsteroidal anti-inflammatory drugs. Pregnant or breastfeeding women should not take this medication, and women planning to become pregnant should use appropriate contraceptive methods. Caution is needed when prescribing to children under 18 years and the elderly, as the safety and efficacy of this medication have not been sufficiently established for these groups. In cases of overdose, symptoms such as hypotension and palpitations may appear, and treatment should be conducted appropriately based on the symptoms. This medication should be stored in a secure place out of reach of children and should not be transferred to another container.
Elevated ALT, elevated AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, sensory impairment, neuromuscular disease, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial swelling, weakness, vascular edema, anaphylaxis, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional dizziness), headache, palpitations, increased blood pressure, lower back pain, increased blood creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including vascular edema, diabetes, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, oculobulbar weakness
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture and kept at room temperature, between 1 to 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and prevent degradation.
White or light yellow round film-coated tablet
30 tablets/box [(10 tablets/Alu-Alu)×3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Korea Hutecs Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.